About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases

Font : A-A+

Highlights
  • Receptor for advanced glycan end-products (RAGE)-specific antagonist chemical compound, FPS-ZM1 has a protective role in COPD.
  • Coronary Obstructive Pulmonary Disease (COPD) is a group of lung conditions which include chronic bronchitis, emphysema and chronic asthma.
  • RAGE was associated with the up-regulation of DAMP-related signaling pathways via Nrf2 (a master regulator of the total antioxidant system in humans).

Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases

A potential drug to combat the life-threatening effects of chronic obstructive pulmonary disease (COPD) has been identified.

A recent study investigated the efficacy of a receptor for advanced glycan end-products (RAGE)-specific antagonist chemical compound, FPS-ZM1, in mice, and found that this compound reverses the inflammatory response and has a protective role in COPD.

Advertisement


COPD is a group of lung conditions which include chronic bronchitis, emphysema and chronic asthma that is fully not reversible. The symptoms include chronic cough with sputum production and breathlessness.

"RAGE disturbances in pulmonary disorders are precise and effective strategies with beneficial clinical effects," said Se-Ran Yang, D.V.M., Ph.D., a researcher involved in the work and an associate professor at the Department of Thoracic and Cardiovascular Surgery in the School of Medicine at Kangwon National University in Gangwon, Korea.
Advertisement

"Blockade of RAGE is a novel clinical therapeutic for COPD ameliorates emphysema/COPD development and progression."

In their study, Yang and colleagues investigated the efficacy of RAGE-specific antagonist FPS-ZM1 administration in both in vivo and in vitro COPD models to determine the molecular mechanism by which RAGE influences COPD.

The researchers injected mice with an in vivo COPD inducer and the RAGE antagonist FPS-ZM1. Then they assessed the infiltrated inflammatory cells and their production of cytokines.

Cellular expression of RAGE, initiating inflammatory response, and soluble RAGE, acting as a "decoy," was determined in protein, serum, and bronchoalveolar lavage fluid in the mice, as well as in the serum of human donors and patients with COPD.

They analyzed downstream damage-associated molecular patterns (DAMPs) and danger signals in vivo and in vitro and in patients with COPD, and found that RAGE was associated with the up-regulation of DAMP-related signaling pathways via Nrf2 (a master regulator of the total antioxidant system in humans). FPS-ZM1 administration also significantly reversed emphysematous lung symptoms in mice.

"No one expected the pathogenic roots of COPD to be simple, and this study gives us an indication of the complexity involved.," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. "The current pharmacological armamentarium is limited, and studies like this are thus extremely valuable as a foundation."

Reference
  1. Hanbyeol Lee et al., Blockade of RAGE ameliorates elastase-induced emphysema development and progression via RAGE-DAMP signaling, The FASEB Journal (2017) http:dx.doi.org/10.1096/fj.201601155R.


Source: Medindia

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Julia Samuel. (2017, February 14). Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases. Medindia. Retrieved on Sep 28, 2022 from https://www.medindia.net/news/healthwatch/potential-new-compound-to-treat-chronic-bronchitis-and-other-lung-diseases-167795-1.htm.

  • MLA

    Julia Samuel. "Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases". Medindia. Sep 28, 2022. <https://www.medindia.net/news/healthwatch/potential-new-compound-to-treat-chronic-bronchitis-and-other-lung-diseases-167795-1.htm>.

  • Chicago

    Julia Samuel. "Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases". Medindia. https://www.medindia.net/news/healthwatch/potential-new-compound-to-treat-chronic-bronchitis-and-other-lung-diseases-167795-1.htm. (accessed Sep 28, 2022).

  • Harvard

    Julia Samuel. 2021. Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases. Medindia, viewed Sep 28, 2022, https://www.medindia.net/news/healthwatch/potential-new-compound-to-treat-chronic-bronchitis-and-other-lung-diseases-167795-1.htm.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Acute Bronchitis Pneumoconiosis Silicosis Chronic Obstructive Pulmonary Disease Cough Symptom Evaluation Bronchitis Emphysema Coughing up Blood Symptom Evaluation Chronic Bronchitis 

Most Popular on Medindia

Diaphragmatic Hernia Sanatogen Color Blindness Calculator Post-Nasal Drip Iron Intake Calculator A-Z Drug Brands in India Drug - Food Interactions How to Reduce School Bag Weight - Simple Tips Accident and Trauma Care Find a Doctor
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT ONLINE WITH A DOCTOR

×

Potential New Compound to Treat Chronic Bronchitis and Other Lung Diseases Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests